SAS (Scandinavian Airlines) Improves Customer Service and Cuts Costs with Scandit’s Barcode Scanning on Smartphones
9.12.2019 10:00:00 EET | Business Wire | Press release
Scandit, the leading enterprise technology platform for mobile computer vision and augmented reality (AR), today announced that SAS (Scandinavian Airlines System) has integrated its powerful scanning software into their new Ground Handling App for smartphones, to replace expensive built-in scanners and upgrade critical ground workflows.
The mobile app (developed by Stockholm-based Objective Solutions) brings new efficiency and cost savings to workflows using mobile scanning of boarding passes, passports, meal vouchers and baggage tags. SAS has deployed the Scandit-powered app to their three Scandinavian airport hubs: Stockholm Arlanda, Oslo Gardermoen, and Copenhagen Kastrup. A detailed case study about the integration is now available.
SAS carries more than 30 million passengers annually to 120 destinations on over 170 aircraft and is widely recognized as a pioneer in digital innovation for the air travel industry. The Ground Handling App is part of a global, digital infrastructure initiative to streamline and improve key operations and improve the travelling experience for their growing volume of passengers. In the first deployment, SAS employees were equipped with 700 Galaxy A8 devices, with further rollouts planned across SAS’ global operations.
The Scandit software was easily integrated into the SAS IT ecosystem. Customer-facing SAS employees use the mobile app from anywhere in the airport, for example at the boarding gate where agents are no longer tied to gate podiums. Passengers are benefiting from a faster, more personalized service and SAS has reduced costs compared to the dedicated scanners and infrastructure. Booking changes can also be done seamlessly with the mobile app and baggage handlers use it to record and track baggage.
“We chose Scandit for its quality and flexibility,” said Fredrik Buxfeldt, Head of Digital Operations IT at SAS. “In addition to barcode scanning and OCR (optical character recognition) in mobile apps, Scandit also enables barcode scanning in websites, so our employees can also use mobile scanning from a browser if they don’t have the mobile app loaded.”
“SAS has reaped the benefits of modernizing data capture workflows with enterprise-grade mobile scanning,” said Samuel Mueller, CEO of Scandit. “We are delighted to play a part in this mobile evolution to help SAS meet its goals for outstanding customer service and operational efficiency.”
Resources
- View the SAS case study: https://www.scandit.com/resources/case-studies/sas/
- Learn more about Scandit’s air travel solutions: https://www.scandit.com/industries/air-travel/
- Download Scandit’s report (Fly High, One Mobile Scan at a Time) to learn how to innovate air travel with mobile computer vision and augmented reality: https://www.scandit.com/resources/whitepapers/fly-high-air-travel/
- Watch this video to see Scandit’s air travel solutions in action: https://www.scandit.com/resources/videos/air-travel-innovation-with-mobile-computer-vision/
- View Scandit’s press kit: https://www.scandit.com/press/
About Scandit
Scandit enables enterprises and consumers to change the way they interact with everyday objects and augment the physical world with real-time data captured by scanning barcodes and recognizing text, objects, and other visual identifiers using smartphones, tablets, wearables, drones, and robots.
Scandit’s mobile data capture platform is built on proprietary computer vision, augmented reality, and machine learning technologies. Companies in industries such as retail, transportation and logistics, manufacturing, and healthcare can use Scandit’s technology to create and power mobile apps for crucial enterprise workflows like search and find, shipping and receiving, inventory management, and proof of delivery.
Many of the world’s most innovative and successful companies are benefiting from Scandit’s enterprise-grade mobile data capture platform, including Alaska Airlines, FedEx, DHL, and PostNL.
For more information, visit https://www.scandit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191208005011/en/
Contact information
Brandon Watts
404-202-3476
brandon@wattsware.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom